Abstract
Cell therapy and regenerative medicine are expected to build the potential industry. However, the potentiality, which might drive economic growth in the future, depends on whether firms enter the market and make profits. This study focuses on Asahi Kasei's new business generation about cell therapy and shows the effectiveness of collaboration with downstream for new entry to the market. Also, it suggests that making system, where upstream and downstream are easier to find opportunities for collaboration with each other, might promote new entry to the market.
